BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Palacaparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Palacaparib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05123482-11177@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Palacaparib: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Palacaparib\, phase 1/2.\nStudy: A Phase I/IIa Study of AZD8205
  Given Alone or Combined\, in Participants With Advanced/Metastatic Solid 
 Malignancies\nEstimated primary completion: 29 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/palacaparib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05123482
URL:https://assetmemo.bio/drug/palacaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05417594-11177@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Palacaparib: Phase 1/2 readout est. (NCT05417594)
DESCRIPTION:Palacaparib\, phase 1/2.\nStudy: Study of AZD9574 as Monotherap
 y and in Combination With Anti-cancer Agents in Participants With Advanced
  Solid Malignancies\nEstimated primary completion: 7 February 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/palacaparib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05417594
URL:https://assetmemo.bio/drug/palacaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-11177@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Palacaparib: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Palacaparib\, phase 1/2.\nStudy: Phase I/IIa Study of AZD5335 a
 s Monotherapy and Combination Therapy in Participants With Solid Tumors\nE
 stimated primary completion: 4 August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/palacaparib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/palacaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181161-11177@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20290118
DTEND;VALUE=DATE:20290119
SUMMARY:Palacaparib: Phase 1/2 readout est. (NCT07181161)
DESCRIPTION:Palacaparib\, phase 1/2.\nStudy: Study of AZD0516 as Monotherap
 y and in Combination in Participants With Metastatic Prostate Cancer\nEsti
 mated primary completion: 18 January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/palacaparib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07181161
URL:https://assetmemo.bio/drug/palacaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590934-11177@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20290925
DTEND;VALUE=DATE:20290926
SUMMARY:Palacaparib: Phase 1/2 readout est. (NCT07590934)
DESCRIPTION:Palacaparib\, phase 1/2.\nStudy: Phase Ib/II Platform Study of 
 Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cance
 r\nEstimated primary completion: 25 September 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/palacaparib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07590934
URL:https://assetmemo.bio/drug/palacaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
